Current Headlines

  1. Arcturus Therapeutics Announces Strategic Collaboration With Johnson & Johnson Innovation To Discover And Develop RNA Medicines
    10/19/2017

    Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  2. Alcobra Ltd. And Arcturus Therapeutics, Inc. Agree To Merge
    10/18/2017

    Alcobra Ltd. and Arcturus Therapeutics, Inc., a privately held biotechnology company developing novel RNA medicines, announced the signing of a definitive agreement to merge the two companies in an all-stock transaction. The transaction will result in a combined company focused on developing novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.

  3. Freeze Drying Webinar Announced For October 25th , 2017
    10/10/2017

    This webinar aims to provide an update on the current scientific state, covering both the basic principles of freezing in a freeze drying cycle as well as the recent developments with regard to control of the freezing stage.

  4. Theragnostics Announces Phase I Results For 68Ga-THP-PSMA In Prostate Cancer
    10/10/2017

    Theragnostics, Ltd., a radiopharmaceuticals company developing products for the diagnosis and treatment of cancer, today announced the results of a phase I study evaluating the safety and biodistribution of 68Ga-THP-PSMA PET/CT in patients with prostate cancer, published in The Journal of Nuclear Medicine (JNM).

  5. Lonza Announces Formation Of New R&D Innovation Center In Israel
    10/9/2017

    Lonza recently announced the establishment of the Lonza Collaborative Innovation Center (CIC) in the new Life Science Park in the outskirts of Haifa, Israel.

  6. Lonza Cell & Gene Therapy Manufacturing Facility On Schedule For 2017 Completion
    10/6/2017

    Lonza has confirmed that its new cell and gene therapy manufacturing facility in Pearland, in the area of Houston, TX (USA), which started construction in May of 2016, is nearing completion and is on schedule to start production in Q1 2018, despite the storms that hit the state of Texas in late August and early September.

  7. Janssen To Invest In Facility Expansion At Ireland Manufacturing Plant
    10/5/2017

    Cork has received a significant jobs boost recently with confirmation by JanssenSciences Ireland that it is to invest more than €300M in an expansion of its manufacturing plant at Ringaskiddy that will create 200 new jobs. By Barry Roche

  8. CRB Responsible For State-Of-The-Art Facility For Abgenix To Produce Biologic Pharmaceuticals
    10/5/2017

    CRB was responsible for designing and building this state-of-the-art facility which produces biologics and biopharmaceuticals for Phase 1-3 clinical studies in cell culture expression systems. The project involved fit-out of approximately 100,000 sq. ft. of space within an existing shell building. The manufacturing area occupies 

  9. Parker Strengthens UK Manufacturing Capabilities
    10/3/2017

    International bioprocessing solutions provider Parker has announced that it has commenced the manufacture of 2D bioprocess container systems in the UK.

  10. G-CON Manufacturing And LifeAire Systems Announce Collaboration
    10/2/2017

    G-CON Manufacturing and LifeAire Systems today announced a collaboration to combine the LifeAire’s air purification technologies within G-CON cleanroom PODs for applications such as cell/tissue culture and gene and cell therapy processes which can benefit from an even higher level of air purity than typically achieved in a cleanroom environment.